Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?

Department of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Italy.
The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry (Impact Factor: 4.24). 02/2010; 18(2):98-116. DOI: 10.1097/JGP.0b013e3181b0fa13
Source: PubMed


Clinical and epidemiologic research has focused on the identification of risk factors that may be modified in predementia syndromes, at a preclinical and early clinical stage of dementing disorders, with specific attention to the role of depression. Our goal was to provide an overview of these studies and more specifically to describe the prevalence and incidence of depression in individuals with mild cognitive impairment (MCI), the possible impact of depressive symptoms on incident MCI, or its progression to dementia and the possible mechanisms behind the observed associations. Prevalence and incidence of depressive symptoms or syndromes in MCI vary as a result of different diagnostic criteria and different sampling and assessment procedures. The prevalence of depression in individuals with MCI was higher in hospital-based studies (median: 44.3%, range: 9%-83%) than in population-based studies (median: 15.7%, range: 3%-63%), reflecting different referral patterns and selection criteria. Incidence of depressive symptoms varied from 11.7 to 26.6/100 person-years in hospital-based and population-based studies. For depressed normal subjects and depressed patients with MCI, the findings on increased risk of incident MCI or its progression to dementia were conflicting. These contrasting findings suggested that the length of the follow-up period, the study design, the sample population, and methodological differences may be central for detecting an association between baseline depression and subsequent development of MCI or its progression to dementia. Assuming that MCI may be the earliest identifiable clinical stage of dementia, depressive symptoms may be an early manifestation rather than a risk factor for dementia and Alzheimer disease, arguing that the underlying neuropathological condition that causes MCI or dementia also causes depressive symptoms. In this scenario, at least in certain subsets of elderly patients, late-life depression, MCI, and dementia could represent a possible clinical continuum.

Download full-text


Available from: Francesco Panza, Mar 03, 2014
  • Source
    • "These results were later included in a large meta-analysis by Ownby and colleagues, which corroborated the notion that a history of depression increases the risk of developing AD (Ownby et al., 2006). Other studies, however, point to depression not as a risk factor, but as an early symptom of the neurodegenerative process of AD, advocating an overlap between the neuropathological events causing cognitive deficits and those causing depressive symptoms in dementia (Kales et al., 2015; Panza et al., 2010; Richard et al., 2013). Considerable structural and functional imaging data support this hypothesis, showing that neuropathological lesions in AD brains correlate with the development of depressive behavior, and may underlie them. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) and major depressive disorder (MDD) are highly prevalent neuropsychiatric conditions with intriguing epidemiological overlaps. Depressed patients are at increased risk of developing late-onset AD, and around one in four AD patients are co-diagnosed with MDD. Microglia are the main cellular effectors of innate immunity in the brain, and their activation is central to neuroinflammation - a ubiquitous process in brain pathology, thought to be a causal factor of both AD and MDD. Microglia serve several physiological functions, including roles in synaptic plasticity and neurogenesis, which may be disrupted in neuroinflammation. Following early work on the 'sickness behavior' of humans and other animals, microglia-derived inflammatory cytokines have been shown to produce depressive-like symptoms when administered exogenously or released in response to infection. MDD patients consistently show increased circulating levels of pro-inflammatory cytokines, and anti-inflammatory drugs show promise for treating depression. Activated microglia are abundant in the AD brain, and concentrate around senile plaques, hallmark lesions composed of aggregated amyloid-β peptide (Aβ). The Aβ burden in affected brains is regulated largely by microglial clearance, and the complex activation state of microglia may be crucial for AD progression. Intriguingly, recent reports have linked soluble Aβ oligomers, toxins that accumulate in AD brains and are thought to cause memory impairment, to increased brain cytokine production and depressive-like behavior in mice. Here, we review recent findings supporting the inflammatory hypotheses of AD and MDD, focusing on microglia as a common player and therapeutic target linking these devastating disorders.
    Full-text · Article · Nov 2015 · Brain Behavior and Immunity
  • Source
    • ", 1997 ; Reynolds et al . , 2006 ; Unützer , 2007 ) . After many years of research , LLD is now con - sidered a multifactorial mood disorder , probably underpinned by several different mechanisms . It has variably been related to vascular disease , neurodegeneration , inflammatory processes and other age - related changes ( Nelson et al . , 2013 ; Panza et al . , 2010 ; Richard et al . , 2013 ) . Furthermore , LLD is still under - recognized and undertreated ; and the outcomes of LLD are broad , including the degree of treatment response ( Ellison et al . , 2012 ; Rojas - Fernandez et al . , 2010 ; World Economic Forum , 2011 ) ."
    [Show abstract] [Hide abstract]
    ABSTRACT: It has been suggested that the serotonin or 5-hydroxytriptamine (5-HT) transporter (5-HTT) and its gene-linked polymorphic region (5-HTTLPR) are selective serotonin reuptake inhibitor (SSRI) response modulators in late-life depression (LLD), and particularly in late-life major depressive disorder (MDD). Previous studies differed in design and results. Our study aimed to investigate the solute carrier family 6 (neurotransmitter transporter and serotonin) member 4 (SLC6A4) gene locus, encoding 5-HTT and SSRI treatment response in late-life MDD. For a prospective cohort study, we enrolled 234 patients with late-life MDD to be treated with escitalopram, sertraline, paroxetine or citalopram for 6 months. The SLC6A4 polymorphisms rs4795541 (5-HTTLPR), rs140701 and rs3813034 genotypes spanning the SLC6A4 locus were investigated in blinded fashion. No placebo group was included. We assessed responder or non-responder phenotypes according to a reduction in the 21-item version of the Hamilton Depression Rating Scale (HDRS-21) score of ⩾ 50%. At follow-up, 30% of the late-life MDD patients were non-responders to SSRI treatment. No time-course of symptoms and responses was made. A poor response was associated with a higher baseline HDRS-21 score. We observed a significant over-representation of the rs4795541-S allele in the responder patients (0.436 versus 0.321; p = 0.023). The single S-allele dose-additive effect had OR = 1.74 (95% CI 1.12-2.69) in the additive regression model. Our findings suggested a possible influence of 5-HTTLPR on the SSRI response in patients with late-life MDD, which is potentially useful in identifying the subgroups of LLD patients whom need a different pharmacological approach. © The Author(s) 2015.
    Full-text · Article · Mar 2015 · Journal of Psychopharmacology
  • Source
    • "Cognitive impairment and depression are two common age-related syndromes, each of which present in approximately a quarter of the elderly population (Bennett and Thomas, 2014, Enache et al., 2011, Marazziti et al., 2010, Potter and Steffens, 2007). While exclusion criteria render problematic the estimation of the comorbidity of depression and cognitive impairment (Huang et al., 2011, Korczyn and Halperin, 2009, Weisenbach et al., 2012), several studies have established depression as a risk factor for cognitive impairment and the development of dementia with age (Gabryelewicz et al., 2007, Katon et al., 2010, Panza et al., 2010). Moreover, the most recent studies convincingly demonstrated objectively measurable deficits in key cognitive functions in a large proportion of patients in the midst of a major depressive episode (Papakostas, 2014, Trivedi and Greer, 2014), for review see (Marazziti, et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Memory deficit is a common manifestation of age-related cognitive impairment, of which depression is a frequently occurring comorbidity. Previously, we developed a submissive (Sub) mouse line, validated as a model of depressive-like behavior. Using learning paradigms testing hippocampus-dependent spatial and nonspatial memory, we demonstrate here that Sub mice developed cognitive impairments at earlier age (3 months), compared with wild-type mice. Furthermore, acute hippocampal slices from Sub animals failed to display paired-pulse facilitation, whereas primed burst stimulation elicited significantly enhanced long-term potentiation in region CA1, relative to control mice. Changes in synaptic plasticity were accompanied by markedly reduced hippocampal messenger RNA expression of insulin-like growth factor and brain-derived neurotrophic factor. Finally, we identified markedly elevated protein levels of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit GluA1 in the hippocampi of Sub mice, which was exacerbated with age. Taken together, the results point to a linkage between depressive-like behavior and the susceptibility to develop age-related cognitive impairment, potentially by hippocampal α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated glutamatergic signaling. Copyright © 2015 Elsevier Inc. All rights reserved.
    Full-text · Article · Feb 2015 · Neurobiology of Aging
Show more